C677T mutation in methylentetrahydrofolatereductase gene in patients with venous thromboses from the central region of Russia correlates with a high risk of pulmonary artery thromboembolism

Terapevticheskii Arkhiv

Volumn 78, Issue 6, 2006, Pages 70-76

  Avdonin, P V ^a   Kirienko, A I ^a   Kozhevnikova, L M ^a   Shostak, N A ^a   Babadaeva, N M ^a   Leontyev, S G ^a   Petukhov, E B ^a   Kubatiev, A A ^a   Savelyev, V S ^a  

^a NONE

Author keywords

Flebothrombosis; Methylentetrahydrofolatereductase (C677T); Polymorphism of genes of coagulation factor V(G1691A); Prothrombin (G20210A); Thromboembolism of pulmonary artery

Indexed keywords

BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASE; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG EMBOLISM; MALE; MIDDLE AGED; POINT MUTATION; RESIDENTIAL CARE; RISK ASSESSMENT; RUSSIAN FEDERATION;

ADOLESCENT; ADULT; AGED; CATCHMENT AREA (HEALTH); FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; PROTHROMBIN; PULMONARY EMBOLISM; RISK ASSESSMENT; RUSSIA;

EID: 33746857652     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Emmerich J. Epidemiology of venous thrombosis. Bull. Acad. Natl. Med. 2003; 187: 19-32; discus.: 32-33.
2. Franco R. F., Reitsma P. H. Genetic risk factors of venous thrombosis. Hum. Genet. 2001; 109: 369-384.
3. Ridker P. M. Inherited risk factors for venous thromboembolism: implications for clinical practice. Clin. Cornerstone 2002; 4: 18-30.
4. Jennings I., Cooper P. Screening for thrombophilia: a laboratory perspective. Br. J. Biomed. Sci. 2003; 60: 39-51.
5. Gathof B. S., Picker S. M., Rojo J. Epidemiology, etiology and diagnosis of venous thrombosis. Eur. J. Med. Res. 2004; 9: 95-103.
6. Goldhaber S. Z. Clinical overview of venous thromboembolism. Vasc. Med. 1998; 3: 35-40.
7. Ferrari E., Baudouy M., Cerboni P. et al. Clinical epidemiology of venous thromboembolic disease. Results of a French Multicentre Registry. Eur. Heart J. 1997; 18: 685-691.
8. Eftychiou V. Clinical diagnosis and management of the patient with deep venous thromboembolism and acute pulmonary embolism. Nurse Pract. 1996; 21: 50-52, 58, 61-62.
9. Kyrle P. A., Eichinger S. The risk of recurrent venous thromboembolism. Vasa 2002; 31: 163-166.
10. Bergqvist D. Postoperative thormboembolism. Berlin: Springer-Verlag; 1983.
11. Brown H. L., Hiett A. K. Deep venous thrombosis and pulmonary embolism. Clin. Obstet. Gynecol. 1996; 39: 87-100.
12. Heilmann L., von Tempelhoff F. G., Gerhold S., Rath W. Effect of thrombophilic factors on thromboembolism and other pregnancy complications. Z. Geburtsh. Neonatol. 2001; 205: 128-136.
13. Diebold J., Lohrs U. Venous thrombosis and pulmonary embolism. A study of 5039 autopsies. Pathol. Res. Pract. 1991; 187: 260-266.
14. Lusiani L., Visona A. I., Bonanome A. et al. The characteristics of the thrombi of the lower limbs, as detected by ultrasonic scanning, do not predict pulmonary embolism. Chest 1996; 110: 996-1000.
15. Meignan M., Rosso J., Gauthier H. et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch. Intern. Med. 2000; 160: 159-164.
16. Emmerich J., Aiach M. Genetic risk factors of thrombosis. Ann. Cardiol. Angeiol. (Paris) 2002; 51: 129-134.
17. Cosmi B., Palareti G. Oral anticoagulant therapy in venous thromboembolism. Semin. Vasc. Med. 2003; 3: 303-314.
18. Zidane M., de Visser M. C., ten Wolde M. et al. Frequency of the TAFI-438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb. Haemost. 2003; 90: 439-445.
19. Watzke H. H. Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors. Wien. Klin. Wschr. 2003; 115: 475-481.
20. Martinelli I., Cattaneo M., Panzeri D., Mannucci P. M. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb. Haemost. 1997; 77: 440-443.
21. Yilmazer M., Kurtay G., Sonmezer M., Akar N. Factor V Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events during pregnancy or the puerperium. Arch. Gynecol. Obstet. 2003; 268: 304-308.
22. Endler G., Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin. Chim. Acta 2003; 330: 31-55.
23. Alvarez A., Barroso A., Robledo M. et al. Prevalence of Factor V Leiden and the G20210A mutation of the prothrombin gene in a random group of patients with thrombotic episodes. Sangre (Barc) 1999; 44: 7-12.
24. Gardner J. Factor V Leiden with deep venous thrombosis. Clin. Lab. Sci. 2003; 16: 6-9.
25. Wahlander K., Larson G., Lindahl T. L. et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb. Haemost. 2002; 87: 580-585.
26. Kuismanen K., Savontaus M. L., Kozlov A. et al. Coagulation factor V Leiden mutation in sudden fatal pulmonary embolism and in a general northern European population sample. Forens. Sci. Int. 1999; 106: 71-75.
27. Bai C., Pan J., Li X. Factor V Leiden and PTG20210A gene mutation in patients with venous thrombosis and healthy blood donors. Zhonghua Yi Xue Za Zhi 1999; 79: 900-902.
28. Seki T., Okayama H., Kumagai T. et al. Arg506Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism. Heart Vessels 1998; 13: 195-198.
29. Manten B., Westendorp R. G., Koster T. et al. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb. Haemost. 1996; 76: 510-513.
30. Zalavras Ch. G., Giotopoulou S., Dokou E. et al. Prevalence of the G20210A prothrombin gene mutation in Northwestern Greece and association with venous thromboembolism. Int. Angiol. 2003; 22: 55-57.
31. Gilchrist A., Solomon N., Erickson D. et al. Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay. Clin. Chim. Acta 2001; 314: 249-254.
32. Margaglione M., Brancaccio V., De Lucia D. et al. Inherited thrombophilic risk factors and venous thromboembolism; distinct role in peripheral deep venous thrombosis and pulmonary embolism Chest 2000; 118: 1405-1411.
33. Middeldorp S., Meinardi J. R., Koopman M. M. et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann. Intern. Med. 2001; 135: 322-327.
34. Kohlmeier R. E., Cho C. G., Bux R. C. et al. Prothrombin gene mutation uncommon in pulmonary embolism. South. Med. J. 2000; 93: 1073-1077.
35. Lu Y., Zhao Y., Liu G. et al. Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population. Thromb. Res. 2002; 106: 7-12.
36. Hainaut P., Jaumotte C., Verhelst D. et al. Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb. Res. 2002; 106: 121-125.
37. Nizankowska-Mogilnicka E., Adamek L., Grzanka P. et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur. Respir. J. 2003; 21: 25-30.
38. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet 2000; 356: 182-183.
39. Emmerich J., Rosendaal F. R., Cattaneo M. et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb. Haemost. 2001; 86: 809-816.
40. Poort S. R., Rosendaal F. R., Reitsma P. H., Bertina R. M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
41. Frosst P., Blom H. J., Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995; 10: 111-113.
42. Bertina R. M., Koeleman B. P., Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
43. Granel B., Morange P. E., Serratrice J. et al. Heterozygous prothrombin gene mutation G20210A and associated diseases. Rev. Med. Interne 2003; 24: 282-287.
44. Dulicek P., Maly J., Safarova M. Risk of thrombosis in patients homozygous and heterozygous for factor V Leiden in the East Bohemian region. Clin. Appl. Thromb. Hemost. 2000; 6: 87-89.
45. Procare Group. Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procare Study. Blood Coagul. Fibrinolys. 2000; 11: 511-518.
46. Martinelli I. Risk factors in venous thromboembolism. Thromb. Haemost. 2001; 86: 395-403.
47. de Moerloose P., Reber G., Perrier A. et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br. J. Haematol. 2000; 110: 125-129.
48. Tosetto A., Missiaglia E., Frezzato M., Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb. Haemost. 1999; 82: 1395-1398.
49. Eichinger S., Weltermann A., Mannhalter C. et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch. Intern. Med. 2002; 162: 2357-2360.
50. De Stefano V., Martinelli I., Mannucci P. M. et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br. J. Haematol. 2001; 113: 630-635.
51. Sciacca F. L., Ciusani E., Silvani A. et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin. Cancer Res. 2004; 10: 1312-1317.
52. Ramacciotti E., Wolosker N., Puech-Leao P. et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb. Res. 2003; 109: 171-174.
53. Wald D. S., Law M., Morris J. K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br. Med. J. 2002; 325: 1202.
54. Quere I., Perneger T. V., Zittoun J. et al. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 2002; 359: 747-752.
55. Brattstrom L., Wilcken D. E., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520-2526.
56. Shmeleva V. M., Kapustin S. I., Papayan L. P. et al. Prevalence of hyperhomocysteinemia and the MTHFR C677T polymorphism in patients with arterial and venous thrombosis from North Western Russia. Thromb. Res. 2003; 111: 351-356.
57. Perrier A. Deep vein thrombosis and pulmonary embolism: a single disease entity with different risk factors? Chest 2000; 118: 1234-1236.
58. Turkstra F., Karemaker R., Kuijer P. M. et al. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb. Haemost. 1999; 81: 345-348.
59. Boyanovsky B., Russeva M., Ganev V. et al. Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patiens with pulmonary thromboembolism and deep venous thrombosis. Blood Coagul. Fibrinolys. 2001; 12: 639-642.
60. Kapustin S. I., Blinov M. N., Kargin V. D. et al. Genetic determinants of hereditary thrombophilia in pathogenesis of venous thrombosis. Ter. Arkh. 2003; 75: 78-80.